The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Zaidi, Shane ^a   McLaughlin, Martin ^a   Bhide, Shreerang A ^a   Eccles, Suzanne A ^a   Workman, Paul ^a   Nutting, Christopher M ^b   Huddart, Robert A ^c   Harrington, Kevin J ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; CHECKPOINT KINASE 1; DOUBLE STRANDED DNA; RAD51 PROTEIN; 5-(2,4-DIHYDROXY-5-ISOPROPYLPHENYL)-4-(4-MORPHOLIN-4-YLMETHYLPHENYL)ISOXAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE; ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90; ISOXAZOLE DERIVATIVE; RADIOSENSITIZING AGENT; RESORCINOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL CYCLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; FEMALE; HEAD AND NECK CARCINOMA; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS; MOUSE; NONHUMAN; PROTEIN DEPLETION; RADIATION EXPOSURE; RADIATION INJURY; RADIOSENSITIZATION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA; ANIMAL; CELL CYCLE CHECKPOINT; DRUG ANTAGONISM; DRUG EFFECT; NUDE MOUSE; PHYSIOLOGY; TUMOR CELL LINE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; FEMALE; HOMOLOGOUS RECOMBINATION; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ISOXAZOLES; MICE; MICE, NUDE; RADIATION-SENSITIZING AGENTS; RESORCINOLS;

EID: 84859857989     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035436     Document Type: Article

References (51)

1. Pearl LH, Prodromou C, Workman P, (2008) The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 410: 439-453.
2. Pearl LH, Prodromou C, (2006) Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 75: 271-294.
3. Trepel J, Mollapour M, Giaccone G, Neckers L, (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10: 537-549.
4. Workman P, Burrows F, Neckers L, Rosen N, (2007) Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 1113: 202-216.
5. Oda T, Hayano T, Miyaso H, Takahashi N, Yamashita T, (2007) Hsp90 regulates the Fanconi anemia DNA damage response pathway. Blood 109: 5016-5026.
6. Arlander SJ, Felts SJ, Wagner JM, Stensgard B, Toft DO, et al. (2006) Chaperoning checkpoint kinase 1 (CHK1), an Hsp90 client, with purified chaperones. J Biol Chem 281: 2989-2998.
7. Camphausen K, Tofilon PJ, (2007) Inhibition of Hsp90: a multitarget approach to radiosensitization. Clin Cancer Res 13: 4326-4330.
8. Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ, (2003) Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res 9: 3749-3755.
9. Dote H, Cerna D, Burgan WE, Camphausen K, Tofilon PJ, (2005) ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition. Cancer Res 65: 6967-6975.
10. Yin X, Zhang H, Lundgren K, Wilson L, Burrows F, et al. (2010) BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer 126: 1216-1225.
11. Machida H, Nakajima S, Shikano N, Nishio J, Okada S, et al. (2005) Heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis. Cancer Sci 96: 911-917.
12. Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, et al. (2004) Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer Res 10: 8077-8084.
13. Machida H, Matsumoto Y, Shirai M, Kubota N, (2003) Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation. Int J Radiat Biol 79: 973-980.
14. Matsumoto Y, Machida H, Kubota N, (2005) Preferential sensitization of tumor cells to radiation by heat shock protein 90 inhibitor geldanamycin. J Radiat Res 46: 215-221.
15. Moran DM, Gawlak G, Jayaprakash MS, Mayar S, Maki CG, (2008) Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells. Oncogene 27: 5567-5577.
16. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, et al. (2003) Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 63: 8984-8995.
17. Dungey FA, Caldecott KW, Chalmers AJ, (2009) Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol Cancer Ther 8: 2243-2254.
18. Kabakov AE, Makarova YM, Malyutina YV, (2008) Radiosensitization of human vascular endothelial cells through Hsp90 inhibition with 17-N-allilamino-17-demethoxygeldanamycin. Int J Radiat Oncol Biol Phys 71: 858-865.
19. Nagengast WB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den Dunnen WF, et al. (2010) 89Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922. Journal of nuclear medicine: official publication, Society of Nuclear Medicine.
20. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, et al. (2008) NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68: 2850-2860.
21. Richardson PG, Chanan-Khan AA, Alsina M, Albitar M, Berman D, et al. (2010) Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. Br J Haematol 150: 438-445.
22. Weigel BJ, Blaney SM, Reid JM, Safgren SL, Bagatell R, et al. (2007) A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res 13: 1789-1793.
23. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, et al. (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23: 4152-4161.
24. Pacey S, Gore M, Chao D, Banerji U, Larkin J, et al. (2010) A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Investigational new drugs DOI:10.1007/s10637-010-9493-4.
25. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, et al. (2008) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 14: 7940-7946.
26. Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, Deluca JK, et al. (2006) A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Investigational new drugs 24: 543-546.
27. Pacey S, Wilson RH, Walton MI, Eatock M, Hardcastle A, et al. (2011) A Phase I study of the Heat Shock Protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced, solid tumors. Clin Cancer Res 17: 1561-1570.
28. Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, et al. (2008) 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 51: 196-218.
29. Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, et al. (2008) NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 10: R33.
30. Stühmer T, Zöllinger A, Siegmund D, Chatterjee M, Grella E, et al. (2008) Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 22: 1604-1612.
31. Gaspar N, Sharp SY, Eccles SA, Gowan S, Popov S, et al. (2010) Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 9: 1219-1233.
32. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, et al. (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577.
33. Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, et al. (2005) Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 11: 7023-7032.
34. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, et al. (2004) Cell death by mitotic catastrophe: a molecular definition. Oncogene 23: 2825-2837.
35. Castedo M, Perfettini JL, Roumier T, Valent A, Raslova H, et al. (2004) Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene 23: 4362-4370.
36. Massey AJ, Schoepfer J, Brough PA, Brueggen J, Chène P, et al. (2010) Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800. Mol Cancer Ther 9: 906-919.
37. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, et al. (2006) Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 103: 17408-17413.
38. Stingl L, Stühmer T, Chatterjee M, Jensen MR, Flentje M, et al. (2010) Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Br J Cancer 102: 1578-1591.
39. Ha K, Fiskus W, Rao R, Balusu R, Venkannagari S, et al. (2011) Hsp90 inhibitor mediated disruption of chaperone association of ATR with Hsp90 sensitizes cancer cells to DNA damage. Mol Cancer Ther.
40. Oude Munnink TH, Korte MA, Nagengast WB, Timmer-Bosscha H, Schröder CP, et al. (2010) (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur J Cancer 46: 678-684.
41. Noguchi M, Yu D, Hirayama R, Ninomiya Y, Sekine E, et al. (2006) Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Biochem Biophys Res Commun 351: 658-663.
42. Merwald H, Kokesch C, Klosner G, Matsui M, Trautinger F, (2006) Induction of the 72-kilodalton heat shock protein and protection from ultraviolet B-induced cell death in human keratinocytes by repetitive exposure to heat shock or 15-deoxy-delta(12,14)-prostaglandin J2. Cell Stress Chaperones 11: 81-88.
43. Gabai VL, O'Callaghan-Sunol C, Meng L, Sherman MY, Yaglom J, (2008) Triggering senescence programs suppresses Chk1 kinase and sensitizes cells to genotoxic stresses. Cancer Res 68: 1834-1842.
44. Gabai V, Sherman M, Yaglom J, (2010) HSP72 depletion suppresses gammaH2AX activation by genotoxic stresses via p53/p21 signaling. Oncogene 29: 1952-1962.
45. Yao Q, Weigel B, Kersey J, (2007) Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. Clin Cancer Res 13: 1591-1600.
46. Lobrich M, Jeggo P, (2007) The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer 7: 861-869.
47. Deckbar D, Birraux J, Krempler A, Tchouandong L, Beucher A, et al. (2007) Chromosome breakage after G2 checkpoint release. J Cell Biol 176: 749-755.
48. Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO, et al. (2003) Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 278: 52572-52577.
49. Koll TT, Feis SS, Wright MH, Teniola MM, Richardson MM, et al. (2008) HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol Cancer Ther 7: 1985-1992.
50. Schwock J, Pham NA, Cao MP, Hedley DW, (2008) Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo. Cancer Chemother Pharmacol 61: 669-681.
51. Tao Y, Leteur C, Calderaro J, Girdler F, Zhang P, et al. (2009) The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe. Cell Cycle 8: 3172-3181.